Literature DB >> 11237599

Identification of the domain in the human interleukin-11 receptor that mediates ligand binding.

K Schleinkofer1, A Dingley, I Tacken, M Federwisch, G Müller-Newen, P C Heinrich, P Vusio, Y Jacques, J Grötzinger.   

Abstract

The interleukin-11 receptor (IL-11R) belongs to the hematopoietic receptor superfamily. The functional receptor complex comprises IL-11, IL-11R and the signal-transducing subunit gp130. The extracellular part of the IL-11R consists of three domains: an N-terminal immunoglobulin-like domain, D1, and two fibronectin-type III-like (FNIII) domains and D2 and D3. The two FNIII domains comprise the cytokine receptor-homology region defined by a set of four conserved cysteine residues in the N-terminal domain (D2) and a WSXWS sequence motif in the C-terminal domain (D3). We investigated the structural and functional role of the third extracellular receptor domain of IL-11R. A molecular model of the human IL-11/IL-11R complex allowed the identification of amino acid residues in IL-11R to be involved in ligand binding. Most of them were located in the third extracellular domain, which therefore should be able to bind with high affinity to IL-11. To prove this prediction, domain D3 of the IL-11R was expressed in Escherichia coli, refolded and purified. For structural characterization, circular dichroism, fluorescence and NMR spectroscopy were used. By plasmon resonance experiments, we show that the ligand-binding capacity of this domain is as high as that one for the whole receptor. These results provide a basis for further structural investigations that could be used for the rational design of potential agonists and antagonists essential in human therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237599     DOI: 10.1006/jmbi.2000.4387

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Inactivation of IL11 signaling causes craniosynostosis, delayed tooth eruption, and supernumerary teeth.

Authors:  Pekka Nieminen; Neil V Morgan; Aimée L Fenwick; Satu Parmanen; Lotta Veistinen; Marja L Mikkola; Peter J van der Spek; Andrew Giraud; Louise Judd; Sirpa Arte; Louise A Brueton; Steven A Wall; Irene M J Mathijssen; Eamonn R Maher; Andrew O M Wilkie; Sven Kreiborg; Irma Thesleff
Journal:  Am J Hum Genet       Date:  2011-07-15       Impact factor: 11.025

2.  The length of the interleukin-11 receptor stalk determines its capacity for classic signaling.

Authors:  Juliane Lokau; Christoph Garbers
Journal:  J Biol Chem       Date:  2018-03-09       Impact factor: 5.157

3.  The binding characteristics of a cyclic nonapeptide, c(CGRRAGGSC), in LNCaP human prostate cancer cells.

Authors:  Chen Gu; Lu Liu; Yujie He; Jianwei Jiang; Zexuan Yang; Qinghua Wu
Journal:  Oncol Lett       Date:  2012-06-21       Impact factor: 2.967

4.  Non-core region modulates interleukin-11 signaling activity: generation of agonist and antagonist variants.

Authors:  Saeko Yanaka; 中冴子 谷; Emiko Sano; 野恵海子 佐; Norio Naruse; 瀬紀男 成; Kin-Ichiro Miura; 浦謹一郎 三; Mutsumi Futatsumori-Sugai; ツ森ー菅井睦美 二; Jose M M Caaveiro; Kouhei Tsumoto; 本浩平 津
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

5.  The structure of the extracellular domains of human interleukin 11α receptor reveals mechanisms of cytokine engagement.

Authors:  Riley D Metcalfe; Kaheina Aizel; Courtney O Zlatic; Paul M Nguyen; Craig J Morton; Daisy Sio-Seng Lio; Heung-Chin Cheng; Renwick C J Dobson; Michael W Parker; Paul R Gooley; Tracy L Putoczki; Michael D W Griffin
Journal:  J Biol Chem       Date:  2020-04-24       Impact factor: 5.157

6.  A designer hyper interleukin 11 (H11) is a biologically active cytokine.

Authors:  Hanna Dams-Kozlowska; Katarzyna Gryska; Eliza Kwiatkowska-Borowczyk; Dariusz Izycki; Stefan Rose-John; Andrzej Mackiewicz
Journal:  BMC Biotechnol       Date:  2012-03-21       Impact factor: 2.563

7.  A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.

Authors:  Marina Cardó-Vila; Amado J Zurita; Ricardo J Giordano; Jessica Sun; Roberto Rangel; Liliana Guzman-Rojas; Cristiane D Anobom; Ana P Valente; Fábio C L Almeida; Johanna Lahdenranta; Mikhail G Kolonin; Wadih Arap; Renata Pasqualini
Journal:  PLoS One       Date:  2008-10-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.